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a b s t r a c t 
The UBR1 ubiquitin ligase promotes degradation of proteins via the N-end rule and by another mech- 
anism that detects a misfolded conformation. Although UBR1 was shown recently to act on protein 
kinases whose misfolding was promoted by inhibition of Hsp90, it was unknown whether this ubiqui- 
tin ligase targeted other client types of the chaperone. We analyzed the role of UBR1 in the degradation
of nuclear receptors that are classical clients of Hsp90. Our results showed that UBR1 deletion results 
in impaired degradation of the glucocorticoid receptor and the androgen receptor but not the estrogen 
receptor α. These ﬁndings demonstrate speciﬁcity in the actions of the UBR1 ubiquitin ligase in the 
degradation of Hsp90 clients in the presence of small molecule inhibitors that promote client misfold- 
ing. 
C © 2013 The Authors. Published by Elsevier B.V. on behalf of Federation of European Biochemical 
Societies. Open access under CC BY license.ntroduction 
The intracellular environment does not favor protein stability. 
ewly made proteins fold under conditions that are relatively hot and 
rowed, which favor misfolding or aggregation rather than acquisi- 
ion of the correct conformation [ 1 ]. These environmental conditions 
ecessitated the evolution of a large cohort of genes that protect 
ewly made proteins or promote degradation of those that misfold. 
he process that is governed by these genes is known variously as pro- 
ein quality control or proteostasis [ 2 , 3 ]. The cellular machinery that 
omprises the proteostasis gene network includes molecular chap- 
rones that interact with newly made or misfolded proteins [ 4 ] and 
omponents of the ubiquitin / proteasome system (UPS) for disposal 
f misfolded proteins [ 5 ]. In addition, the autophagic machinery facil- 
tates disposal of insoluble aggregates that accumulate upon failure 
r imbalance of molecular chaperones or UPS components as cells age 
r upon stress [ 6 ]. The proteostasis network is sensitive to environ- 
ental conditions and adjusts the expression of a variety of genes to 
rotect against proteotoxic stress [ 7 ]. Abbreviations: AR, androgen receptor; CHIP, C-terminal Hsp interacting protein; 
MSO, dimethylsulfoxide; ER, estrogen receptor; GA, geldanamycin; GR, glucocorti- 
oid receptor; HA, hemagglutinin; MEF, mouse embryonic ﬁbroblasts; UPS, ubiquitin 
roteasome system. 
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211-5463 c © 2013 The Authors. Published by Elsevier B.V. on behalf of Federation of Europ
ttp://dx.doi.org/10.1016/j.fob.2013.09.003 The Hsp90 molecular chaperone sits at a hub of the proteostasis 
network by integrating folding of newly made proteins and degrada- 
tion of misfolded ones. The balance of these triage decisions can be 
altered by small molecule inhibitors of Hsp90, which promote client 
protein degradation [ 8 ]. Many of these small molecules are in clinical 
trials as chemotherapeutic agents because of the role Hsp90 plays in 
the folding and degradation of oncogenic protein kinases and nuclear 
receptors [ 9 ]. 
Although it is clear that Hsp90 inhibition results in rapid degra- 
dation of client proteins via the UPS, the mechanisms underlying the 
clearance process are not well characterized. For example, the ubiq- 
uitin ligase C-terminal Hsp interacting protein (CHIP), plays a role 
in the degradation of several Hsp90 clients including protein kinases 
and nuclear receptors [ 10 ]. CHIP is not alone in its capacity to pro- 
mote degradation of misfolded Hsp90 clients and several ubiquitin 
ligases have now been characterized to act in this pathway in yeast 
and mammalian cells [ 11 ]. What is unclear, however, is the speciﬁcity 
by which these ubiquitin ligases promote degradation when Hsp90 is 
inhibited. A good example of this is the glucocorticoid receptor (GR). 
GR can be ubiquitylated in vitro by CHIP [ 12 ] or upon CHIP overex- 
pression [ 13 ], although degradation of this receptor is not affected by 
deletion of CHIP in cells [ 14 ], suggesting that other ubiquitin ligases 
act in a redundant manner. In this report, we show that the ubiquitin 
ligase UBR1 promotes degradation of the GR and the androgen recep- 
tor (AR) but not the estrogen receptor (ER) in cells treated with an 
Hsp90 inhibitor. This ﬁnding is signiﬁcant in view of the direct role of 
the AR in promoting growth of prostate cancer cells. ean Biochemical Societies. Open access under CC BY license.
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Fig. 1. Geldanamycin dependent degradation of GR in WT, Ubr1 −/ − and Chip −/ − MEF 
cells. (A) WT, Ubr1 −/ − and CHIP −/ − MEF cells were treated with 100 nM of GA for 
indicated times. 40 μg of total protein from each cell line were analyzed by SDS–PAGE 
and probed with anti-GR; PI3K was used as a loading control. (B) WT, Ubr1 −/ − and 
CHIP −/ − MEF cells were treated with different concentration of GA for 6 hours. 40 μg 
of total protein from each cell line were fractionated by SDS–PAGE and probed with 
anti-GR. PI3K levels were analyzed as a loading control. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Materials and methods 
Materials 
Geldanamycin was purchased from Invivogen (San Diego, CA),
MG132 was purchased from Calbiochem (San Diego, CA), and both
compounds were dissolved in 100% DMSO. 
Cell culture, transfection and plasmids 
WT, Ubr1 −/ − and Chip −/ − mouse embryonic ﬁbroblast cells
were maintained in DMEM medium supplemented with 10% heat-
inactivated fetal Bovine serum (FBS) (Mediatech Inc., Herdon, VA),
100 units / ml penicillin, 100 μg / ml streptomycin (MP Biomedicals,
LLC, France) and kept at 37 ◦C in 5% CO 2 incubator. The transfec-
tion was performed as described [ 15 ]. For each transfection reaction
4 μg of plasmid DNA was used unless indicated. The plasmid encod-
ing human AR, HA tagged GR and ER- α were gift from Dr. Michael
J. Garabedian (New York School of Medicine). The plasmid encoding
the rat UBR1 was a gift from Dr. Hiroshi Handa (Integrated Research
Institute, Tokyo Institute of Technology, Yokohama, Japan). The WT,
Ubr1 −/ − cells were kind gift from Dr. Yong Tae Kwon (University of
Pittsburg, Pennsylvania) and Chip −/ − cells from Dr. Cam Patterson
(University of North Carolina). 
Western blotting and antibodies 
Cells were transfected or grown to 70–80% conﬂuence and ex-
posed to DMSO, GA and MG132 for indicated time and dose. Lysates
were prepared using lysis buffer containing 50 mM Tris pH 7.5, 2%
SDS, .25% Na-deoxycholate, 150 mM NaCl, 1 mM EDTA, 10% glycerol,
1 mM phenylmethylsulfonyl ﬂuoride, 10 mM NaF, 1 mM Na 3 VO 4 and
protease inhibitors (Complete mini, Roche Diagnostics, Indianapolis,
IN). Lysates were sonicated for 3–4 times, 10 s each time. Protein
concentration of lysates was determined using Bicinchoninic acid
method (Pierce, Rockford, IL). Samples of 40 μg were analyzed in SDS–
polyacrylamide gels and followed the same procedure described pre-
viously [ 15 ]. Antibodies used were: GR (MA1-510, Thermoscientiﬁc,
Rockford, IL, USA), ER- α (sc-543, Santa Cruz Biotechnology, Inc.), AR
[ 16 ]. PI3K (06-497, Millipore). Anti-HA (12CA5 form the Mount Sinai
Hybridoma Facility, New York, NY) and UBR1 (Abcam Inc., Boston,
MA). 
Results 
In previous studies we demonstrated that mammalian UBR1 acted
as part of the quality control apparatus that helps to clear misfolded
protein kinases from cells treated with the Hsp90 inhibitor, gel-
danamycin (GA) [ 15 ]. UBR1 action was at least partially redundant
with CHIP in this capacity. Based on these studies we tested whether
UBR1 acted in the clearance of nuclear receptors, which represent
another well-characterized class of Hsp90 client [ 17 ]. 
We ﬁrst analyzed the ability of GA to promote degradation of the
endogenously expressed GR in mouse embryonic ﬁbroblasts (MEF).
Treatment of cells with 100 nM GA resulted in a very rapid degra-
dation of GR within a two-hour period and these levels were further
diminished after 6 hours of treatment ( Fig. 1 A). GA also promoted
degradation of GR in the UBR1 −/ − cells but at a reduced rate, and
there was still substantial GR remaining after 6 h of treatment. By
contrast, CHIP −/ − cells behaved much like wild type MEFs with re-
spect to GR degradation, as reported by others [ 14 ]. Similar ﬁndings
were made in a dose–response assay where the levels of GR were
barely affected at a dose of 100 nM in UBR1 −/ − cells, whereas in
wild type or CHIP −/ − MEFs the protein was mostly degraded ( Fig. 1 B).
These ﬁndings suggest that UBR1 is important for the degradation ofGR upon Hsp90 inhibition and that additional ubiquitin ligases dis-
tinct from CHIP also act in this capacity. We analyzed whether UBR2,
a UBR1 homolog, acted in a similar capacity to UBR1 but found that
GR degradation was similar in UBR2- / - cells and wild type MEFs (data
not shown). 
To determine the UBR1 dependence on the degradation pheno-
type of UBR1 −/ − cells, we used transfection to introduce wild type rat
UBR1 (rUBR1) into the cells. An HA-tagged version of GR (HA-GR), or
an empty vector as a control were co-transfected into UBR1 −/ − cells
( Fig. 2 A). The effect of rUBR1 overexpression was to cause a large re-
duction in the levels of the transfected HA-GR even without GA treat-
ment. Furthermore, treatment with GA did not lead to a substantial
decrease in the HA-GR levels after 2 h. These ﬁndings suggested that
HA-GR was sensitive to the levels of rUBR1 even in the absence of
GA. The effect of GA was probed by a more prolonged treatment of
18 h ( Fig. 2 B), and in this case we observed that the GA-sensitivity of
the transfected HA-GR was restored. Note also that rUBR1 levels were
also sensitive to GA treatment as described previously [ 15 ]. HA-UBR1
levels were restored upon treatment with the proteasome inhibitor,
MG132, indicating that UBR1 was acting via the UPS as expected, al-
though this also occurred in the vector-transfected control cells, thus
conﬁrming redundancy in UBR1 action. 
The large decrease in HA-GR levels upon co-transfection of rUBR1
( Fig. 2 A) was studied further in a dose–response experiment ( Fig.
2 C). In this case we observed a direct correlation between increasing
rUBR1 concentration and decreasing HA-GR levels, further suggesting
that UBR1 controls GR levels both in the absence and presence of
functional Hsp90. 
The results described thus far suggest that UBR1 promotes degra-
dation of GR and further studies addressed the speciﬁcity of that
function with analysis of the human androgen receptor (hAR) and es-
trogen receptor α (hER α). hAR was transfected into the UBR1 −/ − cells
with either the plasmid overexpressing rat UBR1 or an empty vector.
The ﬁndings ( Fig. 3 A) were very similar those observed for transfec-
tion of HA-GR ( Fig. 2 ). In this case, there was a substantial decrease in
hAR levels when rUBR1 was co-overexpressed in the UBR1 −/ − cells
compared with vector alone even in the absence of GA. In both cases,
however, there was little further effects on degradation of hAR by GA
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Fig. 2. Effect of UBR1 overexpression on GR levels. (A) Ubr1 −/ − cells were transfected 
with human HA-tagged GR (HA-hGR) and pCMV empty vector or rat UBR1. After 24 h 
of transfection the cells were treated with 50 nM of GA or DMSO for the indicated time 
points and harvested. 40 μg of cell lysates were analyzed in SDS–PAGE and probed with 
anti-HA ( α-HA) and UBR1 antisera. PI3K was used as loading control. * in the PI3K blot 
indicates a non- speciﬁc band. (B) Ubr1 −/ − cells were transfected with HA-hGR and 
empty vector or rat UBR1. After transfection cells were treated with DMSO or MG-132 
(50 μM) for 18 h and GA (100 nM) for 6 h. Cells were harvested 24 h after transfection. 
40 μg of cell lysates were analyzed in SDS–PAGE and probed with anti-HA ( α-HA), 
UBR1 and PI3K. (C) Ubr1 −/ − cells were transfected with HA-hGR and different amounts 
of rat E3 ligase UBR1 plasmid DNA (0, 0.5, 2 and 4 μg). Cell were harvested 24 h after 
transfection. 40 μg of total cell lysates were fractionated by SDS–PAGE and probed with 
anti-HA ( α-HA) and UBR1 antisera. PI3K was used as a loading control. NT represents 
non-transfected Ubr1 −/ − MEF cells in A–C. 
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Fig. 3. Effects of UBR1 overexpression on AR and ER- α. (A) Ubr1 −/ − cells were trans- 
fected with the AR expressing plasmid and pCMV empty vector or rat UBR1. After 24 h 
of transfection the cells were treated with different concentrations of GA or vehicle for 
24 h. 40 μg of cell lysates were analyzed in SDS–PAGE and probed with AR and UBR1 
antisera. PI3K was used as loading control. (B) Ubr1 −/ − cells were transfected with AR 
and pCMV empty vector or rat UBR1. After transfection the cells were treated with 
DMSO, MG-132 (50 μM) for 18 h and GA (100 nM) for 6 h. The cells were harvested 24 
h after transfection and 40 μg of cell lysates were analyzed by SDS–PAGE and probed 
with anti AR, UBR1 and PI3K. (C) Ubr1 −/ − cells were transfected a plasmid expressing 
ER- α or pCMV empty vector or rat UBR1. After 24 h of transfection, the cells were 
treated with different concentrations of GA or DMSO for 24 h. 40 μg of cell lysates 
were analyzed by SDS–PAGE and probed with AR and UBR1 antisera. PI3K was used as 
loading control. NT represents non-transfected Ubr1 −/ − MEF cells in A–C. reatment ( Fig. 3 A and B), although rUBR1 levels were sensitive at the 
ighest treatment level of GA. Treatment of these cells with MG132, 
owever, led to a strong resurgence of hAR levels that was particularly 
vident in the cells co-expressing rUBR1. These data strongly support 
 role for UBR1 in the quality control of hAR levels. By contrast, similar 
xperiments with transfected human hER α suggest that UBR1 does 
ot play a similar role in the degradation of this nuclear receptor ( Fig. 
 C). Co-transfection of rUBR1 did not affect hER α in the same man- 
er it did with GR and hAR. Our combined ﬁndings therefore suggest 
peciﬁcity in the actions of UBR1 in the clearance of GR, AR and ER, 
ith the AR displaying the most dependence on UBR1 actions. 
iscussion 
Quality control ubiquitin ligases promote degradation of mis- 
olded proteins. In yeast there exists a small network of quality con- 
rol ubiquitin ligases that function in the degradation of Hsp90 clients 
hat includes UBR1 and at least 7 others acting in the cytosol and the 
ucleus [ 11 ]. In mammalian cells, there are three ubiquitin ligases 
hat are known to facilitate the clearance of protein kinases that mis- 
old upon Hsp90 inhibition and these include CHIP, CUL5 and UBR1 
reviewed in [ 8 ]). It is striking, however, that neither CHIP nor CUL5 
ffect the degradation of GR when they are deleted or down-regulated 
 14 , 18 ], supporting the hypothesis that redundant ubiquitin ligases 
xist. In the studies presented in this report we identify UBR1 as hav- 
ng this speciﬁc function in GR degradation, and also show that UBR1 
cts in the clearance of the hAR, but not hER α. 
UBR1 is a well-characterized ubiquitin ligase that functions via N- 
nd rule degradation and also via non-N-end rule pathways in protein 
uality control [ 19 ]. In yeast, Ubr1 acts via non-N-end rule pathways 
o promote degradation of misfolded proteins [ 20 –22 ] and it seems 
ikely that this will be the case for mammalian UBR1 based on its 
unction in the clearance of nuclear receptors, as shown here, and 
rotein kinases [ 15 ] that misfold upon Hsp90 inhibition. Furthermore, 
ipeptides [ 23 , 24 ] known to inhibit degradation via the N-end rule 
Leu-Ala and Arg-Ala) had no effect on the degradation of GR and AR (data not shown). 
As mentioned above, yeast E3s that act in cytosolic quality control 
are highly redundant. In mammalian cells there is also some redun- 
dancy in the actions of E3 ligases in cellular quality control. In a pre- 
vious study we observed redundancy between CHIP and UBR1 for the 
degradation of CDK4 and AKT protein kinases [ 15 ]. By contrast, there 
does not appear to be a role for CHIP in the degradation of GR that 
misfolds due to Hsp90 inhibition. CHIP can promote GR degradation 
when it is overexpressed, but as discovered by others, CHIP knockout 
cells have no impairment in misfolded GR degradation [ 14 ]. In this 
case, therefore, there appears to be speciﬁcity in E3 action. This speci- 
ﬁcity is further supported by our ﬁnding that overexpression of UBR1 
had no effect on the degradation of ER- α, whereas downregulation of 
CHIP does inhibit ER- α degradation [ 25 ]. 
In conclusion, our ﬁndings provide further support for a conserved 
role for UBR1 in the degradation of misfolded proteins in mammalian 
cells. The ﬁnding that UBR1 acts on some misfolded nuclear receptors 
suggests it may have a role to play in a variety of human diseases of 
aging including cancer as well as Johanson–Blizzard syndrome [ 26 ]. 
Acknowledgments 
We thank Dr. Michael J. Garabedian, Dr. Hiroshi Handa, Dr. Yong 
Tae Kwon and Dr. Cam Patterson for the gift of plasmids and cell lines. 
This work was funded in part by grants from the National Institutes 
of Health (U54CA132378) and NCRR (5G12-RR03060) (CCNY). 
References 
[1] Ellis, R.J. (2007) Protein misassembly: macromolecular crowding and molecular 
chaperones. Adv. Exp. Med. Biol. 594, 1–13 . 
[2] Balch, W.E., Morimoto, R.I., Dillin, A. and Kelly, J.W. (2008) Adapting proteostasis 
for disease intervention. Science 319, 916–919 . 
[3] Wickner, S., Maurizi, M.R. and Gottesman, S. (1999) Posttranslational quality 
control: folding, refolding, and degrading proteins. Science 286, 1888–1893 . 
[4] Hartl, F.U., Bracher, A. and Hayer-Hartl, M. (2011) Molecular chaperones in 
protein folding and proteostasis. Nature 475, 324–332 . 
[5] Hochstrasser, M. (1996) Ubiquitin-dependent protein degradation. Annu. Rev. 
Genet. 30, 405–439 . 
Rasheda Sultana et al. / FEBS Open Bio 3 (2013) 394–397 397 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 [6] Kettern, N., Dreiseidler, M., Tawo, R. and Hohfeld, J. (2010) Chaperone-assisted
degradation: multiple paths to destruction. Biol. Chem. 391, 481–489 . 
[7] Richter, K., Haslbeck, M. and Buchner, J. (2010) The heat shock response: life on
the verge of death. Mol. Cell 40, 253–266 . 
[8] Theodoraki, M.A. and Caplan, A.J. (2012) Quality control and fate determination
of Hsp90 client proteins. Biochim. Biophys. Acta 1823, 683–688 . 
[9] Trepel, J., Mollapour, M., Giaccone, G. and Neckers, L. (2010) Targeting the dy-
namic HSP90 complex in cancer. Nat. Rev. Cancer 10, 537–549 . 
[10] McDonough, H. and Patterson, C. (2003) CHIP: a link between the chaperone
and proteasome systems. Cell Stress Chaperoness 8, 303–308 . 
[11] Theodoraki, M.A., Nillegoda, N.B., Saini, J. and Caplan, A.J. (2012) A network of
ubiquitin ligases is important for the dynamics of misfolded protein aggregates
in yeast. J. Biol. Chem. 287, 23911–23922 . 
[12] Connell, P., Ballinger, C.A., Jiang, J., Wu, Y., Thompson, L.J., Hohfeld, J. et al.
(2001) The co-chaperone CHIP regulates protein triage decisions mediated by
heat-shock proteins. Nat. Cell Biol. 3, 93–96 . 
[13] Cardozo, C.P., Michaud, C., Ost, M.C., Fliss, A.E., Yang, E., Patterson, C. et al.
(2003) C-terminal Hsp-interacting protein slows androgen receptor synthesis
and reduces its rate of degradation. Arch. Biochem. Biophys. 410, 134–140 . 
[14] Morishima, Y., Wang, A.M., Yu, Z., Pratt, W.B., Osawa, Y. and Lieberman, A.P.
(2008) CHIP deletion reveals functional redundancy of E3 ligases in promot-
ing degradation of both signaling proteins and expanded glutamine proteins.
Human Mol. Genet. 17, 3942–3952 . 
[15] Sultana, R., Theodoraki, M.A. and Caplan, A.J. (2012) UBR1 promotes protein
kinase quality control and sensitizes cells to Hsp90 inhibition. Exp. Cell Res.
318, 53–60 . 
[16] Fang, Y., Fliss, A.E., Robins,D.M. and Caplan,A.J. (1996) Hsp90 regulates androgen
receptor hormone binding afﬁnity in vivo. J. Biol. Chem 271, 28697–28702 . [17] Pratt, W.B., Morishima, Y., Murphy, M. and Harrell, M. (2006) Chaperoning of
glucocorticoid receptors Handb. Exp. Pharmacol., 111–138 . 
[18] Ehrlich, E.S. (2009) Regulation of Hsp90 client proteins by a Cullin5-RING E3
ubiquitin ligase. Proc. Natl. Acad. Sci. U.S.A. 106, 20330–20335 . 
[19] Varshavsky, A. (2011) The N-end rule pathway and regulation by proteolysis.
Protein Sci. 20, 1298–1345 . 
[20] Eisele, F. and Wolf, D.H. (2008) Degradation of misfolded protein in the cyto-
plasm is mediated by the ubiquitin ligase Ubr1. FEBS Lett. 582, 4143–4146 . 
[21] Heck, J.W., Cheung, S.K. and Hampton, R.Y. (2010) Cytoplasmic protein quality
control degradation mediated by parallel actions of the E3 ubiquitin ligases Ubr1
and San1. Proc. Natl. Acad. Sci. U.S.A. 107, 1106–1111 . 
[22] Nillegoda, N.B. (2010) Ubr1 and Ubr2 function in a quality control pathway for
degradation of unfolded cytosolic proteins. Mol. Biol. Cell 21, 2102–2116 . 
[23] Baker, R.T. and Varshavsky, A. (1991) Inhibition of the N-end rule pathway in
living cells. Proc. Natl. Acad. Sci. U.S.A. 88, 1090–1094 . 
[24] Du, F., Navarro-Garcia, F., Xia, Z., Tasaki, T. and Varshavsky, A. (2002) Pairs of
dipeptides synergistically activate the binding of substrate by ubiquitin ligase
through dissociation of its autoinhibitory domain. Proc. Natl. Acad. Sci. U.S.A.
99, 14110–14115 . 
[25] Fan, M., Park, A. and Nephew, K.P. (2005) CHIP (carboxyl terminus of Hsc70-
interacting protein) promotes basal and geldanamycin-induced degradation of
estrogen receptor-alpha. Mol. Endocrinol. 19, 2901–2914 . 
[26] Zenker, M. (2005) Deﬁciency of UBR1, a ubiquitin ligase of the N-end rule
pathway, causes pancreatic dysfunction, malformations and mental retardation
(Johanson–Blizzard syndrome). Nat. Genet. 37, 1345–1350 . 
